Cutting Out the Middleman
In the war on drug prices, the middleman is in everyone ’s sights.Announcing his American Patients First blueprint earlier this year, President Trump said one of his “greatest priorities” was to reduce the price of prescription drugs. He added that a key element in delivering this ambition was “very much eliminating” the middlemen.“The middlemen became very, very rich. Whoever those middlemen were – and a lot of people never even figured it out – they’re rich. They won’t be so rich anymore,” he said.While neither the president nor the blueprint itself actually named these middlemen, it would be hard t...
Source: EyeForPharma - December 7, 2018 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news
An Impatient Truth
15 years ago, I introduced the concept of patient centricity at our first ‘Patient Summits’ in London and Philadelphia. At the time, the idea was somewhat alien; pharmaceutical executives were more interested in patient compliance, the science of getting patients to take their medicine as instructed, and driving sales through repeat prescriptions.The existing language of the day was aggressive. It was all about ‘capturing’ market share and ‘dominating’ the minds of customers. I’ll never forget being berated by one delegate because a conference talk had deviated from the agenda – it had morphed into a story ...
Source: EyeForPharma - November 9, 2018 Category: Pharmaceuticals Authors: Paul Simms Source Type: news
An Impatient Truth
15 years ago, I introduced the concept of patient centricity at our first ‘Patient Summits’ in London and Philadelphia. At the time, the idea was somewhat alien; pharmaceutical executives were more interested in patient compliance, the science of getting patients to take their medicine as instructed, and driving sales through repeat prescriptions.The existing language of the day was aggressive. It was all about ‘capturing’ market share and ‘dominating’ the minds of customers. I’ll never forget being berated by one delegate because a conference talk had deviated from the agenda – it had morphed into a story ...
Source: EyeForPharma - November 9, 2018 Category: Pharmaceuticals Authors: Paul Simms Source Type: news
Adherence webinar
Channels: CommercialImage: URL: https://www.eyeforpharma.com/philadelphia/webinar5/?partner=efp-websiteExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - October 18, 2018 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
Tech For The Over-65s
People are living better for longer than ever before, and research has consistently shown that the longer one stays independent in one ’s own home, the happier and healthier one is.[1] There is a clear societal need to meet the practical and emotional burdens of aging in a fast-growing low-dependence group whose quality of life could be transformed with the right level of light-touch care. Pharmaceutical and healthcare players big and small are currently exploring how best to support over-65s in maintaining quality of life. Digital health technology to support patient quality of life is taking hold, and smartphones are...
Source: EyeForPharma - October 18, 2018 Category: Pharmaceuticals Authors: Pamela Walker Source Type: news
Tech For The Over-65s
People are living better for longer than ever before, and research has consistently shown that the longer one stays independent in one ’s own home, the happier and healthier one is.[1] There is a clear societal need to meet the practical and emotional burdens of aging in a fast-growing low-dependence group whose quality of life could be transformed with the right level of light-touch care. Pharmaceutical and healthcare players big and small are currently exploring how best to support over-65s in maintaining quality of life. Digital health technology to support patient quality of life is taking hold, and smartphones are...
Source: EyeForPharma - October 18, 2018 Category: Pharmaceuticals Authors: Pamela Walker Source Type: news
Working with HTAs: It ’s Your Move
In June last year, the heads of European health technology assessment (HTA) bodies came together at a meeting facilitated by EUnetHTA (European Network for Health Technology Assessment) and the European Commission ’s Directorate General for Health and Food Safety.A key focus of the event was the creation of earlier and more engaging dialogue between pharma and HTA bodies. This is not surprising. As critical gatekeepers for new medicine seeking access to national markets, HTAs are playing central roles in moves to tighten control over drug spending across Europe. As part of this, bodies are going further than ever before ...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Ross Davies Source Type: news
Value: A Balancing Act
There are perhaps few buzzwords bandied around in pharma circles as much in recent years as ‘value’. Companies are actively competing to stress value over volume and highlight their zealous efforts to go well ‘beyond the pill’ and deliver real value for every stakeholder in healthcare, from the patient up.A cynic might suggest that such talk is simply pharma marketing speak but, with ever-tightened purse strings, payers are demanding that pharma delivers on its promises, as they seek to understand how much bang for their buck they can expect when they purchase drugs.“We are over the tipping point,” says Zhen Su...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Ross Davies Source Type: news
